StockMarketWire.com - Indivior said Friday that Health Canada had approved its opioid addiction treatment paving the way for the company to begin sales in Canada by the second half of 2019.

The company said its opioid addiction treatment Sublocade would be marketed by Indivior Canada.

Illicit opioid use in Canada is a national public health crisis that continued to grow, with 3,005 and 3,996 apparent opioid-related deaths in 2016 and 2017 respectively, the company said.

The approval from Health Canada followed approval of Sublocade by the U.S. Food and Drug Administration (FDA) on November 30.

'We are committed to helping the patients, families and communities impacted by the opioid epidemic around the world,' said Shaun Thaxter, Chief Executive Office of Indivior.

'The approval of SUBLOCADE in Canada is an important milestone, and we look forward to continuing to partner with the Canadian treatment community to help those with opioid use disorder.'



Story provided by StockMarketWire.com